ET
GSK icon

Equitable Trust’s GSK GSK Stock Holding History

Equitable Trust’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-16,692
Closed -$908K – 391
2022
Q2 		$908K Buy
16,692
+526
+3% +$29K 0.07% 188
2022
Q1 		$881K Buy
16,166
+233
+1% +$12.7K 0.06% 188
2021
Q4 		$878K Buy
15,933
+1,223
+8% +$63.6K 0.05% 189
2021
Q3 		$703K Buy
14,710
+2,149
+17% +$108K 0.04% 205
2021
Q2 		$625K Buy
12,561
+2,179
+21% +$105K 0.04% 226
2021
Q1 		$463K Buy
10,382
+4,075
+65% +$185K 0.03% 253
2020
Q4 		$290K Buy
6,307
+256
+4% +$11.8K 0.02% 297
2020
Q3 		$284K Sell
6,051
-6,487
-52% -$325K 0.02% 281
2020
Q2 		$639K Buy
12,538
+578
+5% +$29.7K 0.06% 196
2020
Q1 		$567K Buy
11,960
+8,443
+240% +$450K 0.06% 195
2019
Q4 		$206K Buy
+3,517
New +$196K 0.02% 275

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Equitable Trust's GSK Position: Q3 2022 in Review

Equitable Trust sold out of GSK (GSK) in Q3 2022, closing a stake of 16,692 shares — an estimated $908K sold.

Equitable Trust first reported a position in GSK in Q4 2019 and held it in 11 quarters. The position peaked at $908K in Q2 2022. 742 funds tracked by Wall St. Rank hold GSK as of Q3 2022.

  • Equitable Trust reported no remaining GSK position as of Q3 2022 after selling out during the quarter.
  • Equitable Trust sold 16,692 GSK shares in Q3 2022, an estimated $908K.
  • Equitable Trust first reported a position in GSK in Q4 2019 and held it in 11 quarters.
  • Equitable Trust's GSK position peaked at $908K in Q2 2022.
  • 742 funds tracked by Wall St. Rank held GSK as of Q3 2022.

Based on Equitable Trust's 13F filing for Q3 2022, filed 31 Oct 2022.